Pharma Told To Maintain Drug Stockpiles Despite Six-Month Brexit Delay
An agreement to delay Brexit has brought no reprieve for the pharmaceutical sector, which must remain at a heightened state of preparedness as a no-deal scenario is still a possibility. Industry says it will seek clarity on the practical implications of this.
You may also be interested in...
UK Pharma Sector ‘Not Ready’ For No-Deal Brexit
A leaked government note has thrown doubt on the ability of the pharma sector to be ready for a no-deal Brexit in October, even though some of the contenders to be the next prime minister say there is nothing to fear from the UK leaving the EU without a deal.
UK BIA To Lobby New EU Parliament On Need For Close Regulatory Ties After Brexit
The BioIndustry Association wants to discuss the importance of close post-Brexit regulatory alignment with the new European Parliament and will also press its message on the next leader of the Conservative Party after prime minister Theresa May steps down.
WHO Consults On Updates To 24-Year-Old GMP Requirements For Pharma Excipients
The World Health Organization wants to update its guideline on manufacturing pharmaceutical excipients to ensure these products meet the requirements for quality and purity that they purport or are represented to possess.